

Cell-Free Fetal DNA Testing (for North Carolina Only)

Policy Number: CSNCT0560.08
Effective Date: August 1, 2025

[➔ Instructions for Use](#)

Table of Contents	Page
Application	1
Coverage Rationale	1
Applicable Codes	1
U.S. Food and Drug Administration	2
References	2
Policy History/Revision Information	2
Instructions for Use	3

Related Policy
<ul style="list-style-type: none"> Chromosome Microarray Testing (Non-Oncology Conditions) (for North Carolina Only)

Application

This Medical Policy only applies to the state of North Carolina.

Coverage Rationale

For medical necessity clinical coverage criteria, refer to the [North Carolina Medicaid \(Division of Health Benefits\) Clinical Coverage Policy, Laboratory Services: 1S-10, Genetic Testing for Carrier and Prenatal](#).

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines may apply.

CPT Code	Description
*0060U	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood
*0168U	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma without fetal fraction cutoff, algorithm reported as a risk score for each trisomy
*0488U	Obstetrics (fetal antigen noninvasive prenatal test), cell-free DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies, reported as selected antigen(s) detected or not detected
*0489U	Obstetrics (single-gene noninvasive prenatal test), cell-free DNA sequence analysis of 1 or more targets (e.g., CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to determine fetal inheritance of maternal mutation, algorithm reported as a fetal risk score for the condition (e.g., cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia)
*0494U	Red blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative

CPT Code	Description
*0536U	Red blood cell antigen (fetal RhD), PCR analysis of exon 4 of RHD gene and housekeeping control gene GAPDH from whole blood in pregnant individuals at 10+ weeks gestation known to be RhD negative, reported as fetal RhD status
81422	Fetal chromosomal microdeletion(s) genomic sequence analysis (e.g., DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood
*81479	Unlisted molecular pathology procedure

CPT® is a registered trademark of the American Medical Association

Codes labeled with an asterisk (*) are not on the State of North Carolina Medicaid Fee Schedule and therefore may not be covered by the State of North Carolina Medicaid Program.

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Laboratories that perform DNA-based tests are regulated by the FDA under the Clinical Laboratory Improvement Amendments. Refer to the following website for more information: <https://www.fda.gov/medical-devices/ivd-regulatory-assistance/clinical-laboratory-improvement-amendments-clia>. (Accessed April 16, 2025)

A list of nucleic acid-based tests that have been cleared or approved by the FDA Center for Devices and Radiological Health is available at: <https://www.fda.gov/medical-devices/in-vitro-diagnostics/nucleic-acid-based-tests>. (Accessed April 16, 2025)

References

North Carolina Division of Health Benefits (NCDHHS), Clinical Coverage Policies, Genetic Testing for Carrier, and Prenatal No: 1S-10. <https://medicaid.ncdhhs.gov/media/14679/download?attachment>. Available at: Accessed April 16, 2025.

Policy History/Revision Information

Date	Summary of Changes
08/01/2025	<p>Coverage Rationale</p> <ul style="list-style-type: none"> Replaced instruction to “refer to the North Carolina Medicaid (Division of Health Benefits) Clinical Coverage Policy, Laboratory Services: 1S-4, <i>Genetic Testing</i> for medical necessity clinical coverage criteria” with “refer to the North Carolina Medicaid (Division of Health Benefits) Clinical Coverage Policy, Laboratory Services: 1S-10, <i>Genetic Testing for Carrier and Prenatal</i> for medical necessity clinical coverage criteria” <p>Applicable Codes</p> <ul style="list-style-type: none"> Added CPT code 0536U Removed CPT codes 0327U, 81420, and 81507 Added notation to indicate CPT code 0536U are not on the State of North Carolina Medicaid Fee Schedule and therefore may not be covered by the State of North Carolina Medicaid Program Removed list of ICD-10 diagnosis codes: O09.00, O09.01, O09.02, O09.03, O09.10, O09.11, O09.12, O09.13, O09.211, O09.212, O09.213, O09.219, O09.291, O09.292, O09.293, O09.299, O09.30, O09.31, O09.32, O09.33, O09.40, O09.41, O09.42, O09.43, O09.511, O09.512, O09.513, O09.519, O09.521, O09.522, O09.523, O09.529, O09.611, O09.612, O09.613, O09.619, O09.621, O09.622, O09.623, O09.629, O09.70, O09.71, O09.72, O09.73, O09.811, O09.812, O09.813, O09.819, O09.821, O09.822, O09.823, O09.829, O09.891, O09.892, O09.893, O09.899, O09.90, O09.91, O09.92, O09.93, O09.A0, O09.A1, O09.A2, O09.A3, O26.20, O26.21, O26.22, O26.23, O26.841, O26.842, O26.843, O26.849, O26.851, O26.852, O26.853, O26.859, O26.891, O26.892, O26.893, O26.899, O26.90, O26.91, O26.92, O26.93, O28.0, O28.1, O28.2, O28.3, O28.4, O28.5, O28.8, O28.9, O30.001, O30.002, O30.003, O30.009, O30.011, O30.012, O30.013, O30.019, O30.021, O30.022, O30.023, O30.029, O30.031, O30.032, O30.033, O30.039, O30.041, O30.042, O30.043, O30.049,

Date	Summary of Changes
	<p>O30.091, O30.092, O30.093, O30.099, O35.00X0, O35.01X0, O35.02X0, O35.03X0, O35.04X0, O35.05X0, O35.06X0, O35.07X0, O35.08X0, O35.09X0, O35.10X0, O35.11X0, O35.12X0, O35.13X0, O35.14X0, O35.15X0, O35.19X0, O35.2XX0, O35.AXX0, O35.BXX0, O35.CXX0, O35.DXX0, O35.EXX0, O35.FXX0, O35.GXX0, O35.HXX0, O99.210, O99.211, O99.212, O99.213, O99.280, O99.281, O99.282, O99.283, O99.284, O99.285, O99.310, O99.311, O99.312, O99.313, O99.320, O99.321, O99.322, O99.323, O99.330, O99.331, O99.332, O99.333, O99.340, O99.341, O99.342, O99.343, O99.810, O99.814, Q95.0, Q95.1, Q95.2, Q95.3, Q95.5, Q95.8, Q95.9, Z34.00, Z34.01, Z34.02, Z34.03, Z34.80, Z34.81, Z34.82, Z34.83, Z34.90, Z34.91, Z34.92, Z34.93, Z36.0, Z36.1, Z36.2, Z36.3, Z36.4, Z36.5, Z36.81, Z36.82, Z36.83, Z36.89, Z36.8A, Z36.9, Z3A.09, Z3A.10, Z3A.11, Z3A.12, Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19, Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28, Z3A.29, Z3A.30, Z3A.31, Z3A.32, Z3A.33, Z3A.34, Z3A.35, Z3A.36, Z3A.37, Z3A.38, Z3A.39, Z3A.40, Z3A.41, Z3A.42, and Z3A.49</p> <p>Supporting Information</p> <ul style="list-style-type: none"> Updated <i>FDA</i> and <i>References</i> sections to reflect the most current information Archived previous policy version CSNCT0560.07

Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state, or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state, or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state, or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state, or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.